SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVR and ONLY ADVR
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire6/26/2007 8:22:44 PM
   of 278
 
Health Canada Approves ADVR's Application for Clinical IND
Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today that a Clinical Trial Application for the use of AVR118 in cancer patients has been approved by the Therapeutic Products Division of Health Canada. This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.

“Our objective in seeking regulatory approval in Canada is to expand our clinical trial network in sites where we can accrue patients quickly and efficiently,” said Stephen M. Elliston, President and CEO of Advanced Viral Research Corp. “Large Canadian academic healthcare institutions typically enroll a higher proportion of patients into NCI-sponsored trials than their U.S. counterparts. Furthermore, the U.S. FDA recognizes Canadian centers as being fully compliant with U.S. clinical standards,” added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News